Consort Medical Share Discussion Threads

[wjccghcc] 04/12/2010 18:17

... and their results have been pretty mediocre during those periods apart from this one!

[cerrito] 03/12/2010 21:02

I thought they were good but not excellent results; may need to have patience to get over 500p but continue to be reliable.
I liked the cash flows produced in the last six months ie net operating cash post interest and taxes of £8.2m; capex at £2.6m and with dividends(which make up the bigger full year dividend) of £3.5m that allowed them to reduce borrowings.

WJCCGHCC- you are correct to say that they use the word challenging but they always do..or to be more precise if you look at the forward statement in the three results before this one(ie June 2010;December 09;June 09) you will find the word challenging.

[wjccghcc] 02/12/2010 13:17

Not sure the outlook waas that positive. It described the US as challenging.

[uhound] 02/12/2010 10:53

Good results and positive outlook - Press coverage to give the shares a boost?

[uhound] 01/12/2010 11:30

Interim Results due tomorrow.

Would expect more positive news - anyone following?

[cerrito] 16/9/2010 23:12

note good run and also that Investec have downgraded from buy to hold with a 462p price target.

[polar fox] 13/9/2010 14:17

When CSRT approached AMS last February, the market cap. was around £53m, fully diluted. Today, AMS' share price has hit a 12-yr high at 60p, valuing the company at around £93m, fully diluted. Adding a bid premium, AMS is now probably out of CSRT's reach, even if they have any interest in re-approaching after the 18th.

As an AMS shareholder, I noticed that CSRT's share price bottomed at 340p a few days after a new NOMAD was appointed, and it's been trending up ever since. My suspicion was that it was in preparation for an aggressive Rights Issue. But I think it's over now, for CSRT.

GL everyone. CSRT now needs to worry again about being a target itself. Shouldn't be bad for the SP!

[polar fox] 08/9/2010 08:19

Sparkling Interims from AMS this morning - fully deserving its Zulu Principle top-slot. Now, will CSRT want to have another go after Sept.18? Can they persuade the City to put up the significant, and rising, total cost? In any case, it seems more likely that one of AMS' clutch of US multinational partners will make an all-cash offer at some point. Worth watching.

[polar fox] 26/8/2010 21:11

CSRT will be free to re-approach AMS from Sept.18. AMS' interims are out on Sept.8. Once a boardroom makes a decision to go for a company, they rarely just give up, in my experience. Can CSRT come up with around £125m? A dilutive Rights Issue is an outside possibility perhaps. Keep a wary eye open....

[value viper] 25/8/2010 08:02

pushing through £4 nicely now - seems to me that this co is basically all ex- Celltech execs (Celltech was taken over) - reckon they know their onions and could be an acquisition target too imv - nri.

[touch2002] 24/8/2010 22:22

VV - I'd agree, not expensive on any valuation measure and the potential for positive newsflow (M&A, new product wins/partnerships, dose counters) probably outweighs the negative (Advair patent, slow US margin decline).

Remain a holder.

[value viper] 19/8/2010 19:57

top end of range here - looking for a breakout IF it can get thru £4.
not expensive and a good yield imv - nri.

[simon gordon] 28/10/2009 14:25

Sold out this morning. The more digging I did the more I realised that CSRT have a real slog ahead, the main reason is that Advair's patent is running out in the next few years, whilst it won't hammer the company it is just a big negative rather than a growth positive. Share will probably flatline for much of 2010.

[simon gordon] 08/10/2009 12:15

Bought in this morning. With a fair wind it could be back at 600p in 2010.

[cerrito] 27/8/2009 22:29

Glad to see a thread has been set up for them
been in them for two years plus and first bought in at around 750p when they were called bepak and everyone was excited by exubera.Since then have been in and out and have averaged down to 560
not looking to sell and perhaps buy some more
something you put away I guess there will be a bid in the next 12/15 months for something between 400 and 500.
Good solid people
pretty low profile but I quote the following from Tempus in the Times on June 25; as you can see the market did not follow Tempus' advice
quote
The last time this column caught up with Consort Medical, it was called Bespak, its shares were trading at 664p and its inability to produce profit growth precluded Tempus from taking a positive stance. In the two years since, shares in the medical devices maker have fallen 41 per cent and, although it has changed its chief executive as well as its name, the bottom line has stayed stubbornly the same.
Wednesday's full-year results showed that, at £17.9 million, pre-tax profits were once again flat. But Consort has had to run merely to stand still. When Pfizer withdraw Exubera, its inhaled insulin drug, in 2007, Consort - which made the inhaler - lost its biggest customer and £20 million in sales at a stroke. Since then, Consort, now run by Jon Glenn, has sought to fill that hole through product launches and emerging market growth in its asthma-inhaler division, and by expanding the overseas presence of King Systems, its American maker of disposable surgical equipment. The problem is that recession has brought pressure on prices, destocking by distributors and a downturn in elective surgery in the US, either because prospective patients lack funds or are unwilling to take time off work at a time of job insecurity.
Consort's shares have also been held back by uncertainty over the 8 per cent stake held by Kaupthing, now in administration. At 391p, or nine times earnings, and yielding 5 per cent, the shares are a bet on Mr Glenn's turnaround efforts. A strong balance sheet, a low valuation and progress to date give him the benefit of the doubt. Buy.

[investinggarden] 04/8/2009 09:14

Buy recommendation from Growth Company Investor

[aileron] 20/7/2009 09:06

well after much deliberation Ive gone for inchcape instead of consort. still have consort as a limit buy for a smaller amount at 350p and i'll let it run til expiry. didnt realise consort had such a big spread, and small volumes.

cheers v v and good luck

[value viper] 02/7/2009 11:43

buy advice in 'shares mag' today fwiw

[aileron] 29/6/2009 21:32

hmmm didnt think my target price would be reached so quick. initial target to buy was 350. im going to cancel and go for a lower price. seems to be going in one direction for now.

[value viper] 29/6/2009 09:42

horribly illiquid isnt it ?

[aileron] 27/6/2009 10:37

limit order placed to buy, expires end of july. price is falling......patience is a virtue. will post back if limit price reached!

[aileron] 25/6/2009 14:48

hello,

bit of a coincidence? trawling through the paper this morning and the results also intrigued me. a little suprised that this was the only thread here though.

but.....perhaps this is a good thing?

any other fans of csrt out there?

[value viper] 25/6/2009 08:49

I think this looks promising. Robust performance in a recession.